Latest information on COVID-19
Support teaching, research, and patient care.
Historically, children have represented an understudied, ‘orphan’ population in the field of therapeutics. Many medicines used in children have not been rigorously tested and lack the same level of evidence to help guide dosing as compared to adults. Yet, an in-depth understanding of a drug's clinical pharmacology is essential for its safe and effective use in children. Further, traditional “one-size fits all” approaches to pediatric therapeutics will continue be inadequate due to the known heterogeneity in children resulting from ongoing growth and maturation. Individualized frameworks for dose decision-making during clinical care are imperative.My clinical research program is focused on improving child health by promoting the safe and efficacious use of medications in children. It supports the advancement of pediatric therapeutics through the application of quantitative pharmacokinetic (PK) and pharmacodynamic (PD) frameworks to inform dose-decision. Translation of research findings back to clinical care is essential and facilitated through the development of clinical decision support dosing platforms integrated within the electronic health record (EHR), allowing real-time precision dosing at the point of care. My work further supports the clinical development of re-purposed and novel therapies in infants and children.Learn about the Importance of Children in Clinical Studies - https://www.nih.gov/health-information/nih-clinical-research-trials-you/parents-children
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with
cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute
Stanford is currently not accepting patients for this trial.
For more information, please contact Nancy Sweeters, RN, PNP, 650-721-4074.
View full details